NIH R01 submission, “JAK1/2 as Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target” Receives a Fundable Score

Dr. Fajgenbaum’s submission to the NIH received a fundable score (12th percentile!). A number of individuals on the translational research team were involved in proofreading/editing the grant and getting all the experiments done for preliminary data. This grant will bring together a number of researchers across Penn and other academic institutions.